{"id":15,"date":"2016-10-21T11:52:21","date_gmt":"2016-10-21T11:52:21","guid":{"rendered":"http:\/\/users.utu.fi\/manmat\/?page_id=15"},"modified":"2026-04-06T14:42:55","modified_gmt":"2026-04-06T11:42:55","slug":"publications","status":"publish","type":"page","link":"https:\/\/users.utu.fi\/manmat\/publications\/","title":{"rendered":"Publications"},"content":{"rendered":"

Published peer-reviewed articles<\/strong><\/h4>\n
    \n
  1. Misin O, Piispanen A, Matilainen M<\/span>, Parkkola R, Nyman M, Sainio T, Hirvonen J & Airas L<\/strong> (2026): Real-world detection of paramagnetic rim lesions and their association with disease burden in multiple sclerosis<\/em><\/a>, Multiple Sclerosis and Related Disorders, 107, 107012<\/li>\n
  2. Hallinen M, Leino O, Laaksonen I, Matilainen M<\/span> & Ekman E <\/strong>(2025): A nationwide comparison of public and private treatment of Achilles tendon rupture in Finland<\/em><\/a>, Scandinavian Journal of Surgery, <\/i>0(0)<\/li>\n
  3. Laaksonen S, Sucksdorff M, Vuorimaa A, Kuhle J, Nylund M, Rajander J, Wahlroos S, Matilainen M<\/span>, Saraste M & Airas L<\/strong> (2025): Predictors of risk of secondary progression in multiple sclerosis<\/em><\/a>, Therapeutic Advances in Neurological Disorders, 18:17562864251357276<\/li>\n
  4. Nylund M, Lehto J, Matilainen M<\/span>, Rajander J, Wahlroos S, Sucksdorff M, Kuhlmann T & Airas L<\/strong> (2025): Longitudinal accumulation of glial activation measured by TSPO-PET predicts later brain atrophy in multiple sclerosis<\/em><\/a>, Journal of Neuroinflammation, 22, 200<\/li>\n
  5. Luoma A, Matilainen M<\/span>, Tuisku J M, Aarnio R, Nikkil\u00e4 T, Laaksonen S, Koivum\u00e4ki M, Honkonen E, Nylund M, Wahlroos S, Solin O, Chen M K, Toyonaga T, Lehto J, Snellman A, Rinne J O & Airas L M<\/strong> (2025): Synaptic Density in Multiple Sclerosis: An In Vivo Study Using [11C]UCB-J-PET Imaging<\/a><\/em>, Neurology – Neuroimmunology & Neuroinflammation, 12(5), e200435<\/li>\n
  6. Sj\u00f6ros T, Saraste M, Matilainen M<\/span>, Nylund M, Koivum\u00e4ki M, Kuhle J, Leppert D & Airas L <\/strong>(2025): Serum glial fibrillary acid protein associates with TSPO-expressing lesions in multiple sclerosis brain<\/em><\/a>, Therapeutic Advances in Neurological Disorders, 18:17562864251352998<\/li>\n
  7. Mansuri N, Hashimi H, Matilainen M<\/span>, Alzgheid A, Alsagher M, Buhmeida A, Jbireal J M & Kronqvist P<\/strong> (2025): Breast Cancer Molecular Subtypes in Libyan Women: Incidence and Prognostic Value of Securin and Separase<\/em><\/a>, AlQalam Journal of Medical and Applied Sciences, 2132\u20132143<\/li>\n
  8. Alfaifi B Q, Tuisku J, Matilainen M<\/span>, Anton-Rodriguez J, Lewis D, Jackson A, Coope D J, Airas L, Deakin B, Herholz K, Gerhard A & Hinz R<\/strong> (2025): Hemispheric asymmetry of [11C](R)PK11195 binding to translocator protein 18\u2009kDa (TSPO) in normal brain<\/em><\/a>, Journal of Cerebral Blood Flow & Metabolism, 45(11): 2146-2160.<\/li>\n
  9. Ahola V, Saraste M, Nylund M, Matilainen M<\/span>, Luoma A, Vuorimaa A, Lehto J, Laaksonen S,\u00a0 Brockmann E-C, Kuhle J, Leppert D, Soukka T, Lamminm\u00e4ki U & Airas L<\/strong> (2025): Plasma CHI3L1 associates with brain volume loss and glial activation in multiple sclerosis<\/em><\/a>, Journal of Neurology, Neurosurgery and Psychiatry, 96, <\/span>1053-1060.<\/span><\/li>\n
  10. Klotz L, Smolders J, Lehto J, Matilainen M<\/span>, L\u00fctje L, Buchholz L, Albrecht S, Walter C, Varghese J, Wiendl H, Nylund M, Thomas C, Gardberg M, van den Bosch A M R, Airas L, Huitinga I & Kuhlmann T<\/strong> (2025): Broad rim lesions are a new pathological and imaging biomarker for rapid disease progression in multiple sclerosis<\/a><\/em>, Nature Medicine, 31, 2016\u20132026.<\/li>\n
  11. Radford-Smith D E, Yates A G, Kacerova T, Nylund M, Sucksdorff M, Matilainen M<\/span>, Willemse E, Oechtering J, Maleska Maceski A, Leppert L, Kuhle J, Probert F, Anthony D C & Airas L<\/strong> (2025): Integrating TSPO-PET imaging with metabolomics for enhanced prognostic accuracy in multiple sclerosis<\/em><\/a>, BMJ Neurology Open, 7(1):e001026<\/li>\n
  12. Roivas I A, Leino O K, Lehtim\u00e4ki K K, Matilainen M<\/span>\u00a0& Ekman E<\/strong> (2025): Proximal humeral fractures in Finland: regional differences in incidence and methods of treatment<\/em><\/a>, 34(4), 1081-1087<\/li>\n
  13. Leino O K, Forsbacka N, Laaksonen I E, M\u00e4kel\u00e4 K T, Matilainen M<\/span> & Ekman E M<\/strong> (2024): Changing treatment of hip fractures in Finland<\/em><\/a>, Archives of Orthopaedic and Trauma Surgery, 144, <\/span>3469\u20133478.<\/li>\n
  14. Hallinen M, Sallinen H, Keskinen H, Matilainen M<\/span> & Ekman, E<\/strong> (2024): Regional variations in incidence and treatment trends of Achilles tendon ruptures in Finland : a nationwide study<\/em><\/a>, Acta Orthopaedica<\/i>, 95<\/i>, 401\u2013406.<\/li>\n
  15. Alzghool O M, Aarnio R, Helin J S, Wahlroos S, Keller T, Matilainen M<\/span>, Solis J, Danon J J, Kassiou M, Snellman A, Solin O, Rinne J O & Haaparanta-Solin M<\/strong> (2024): Glial reactivity in a mouse model of beta-amyloid deposition assessed by PET imaging of P2X7 receptor and TSPO using [11<\/sup>C]SMW139 and [18<\/sup>F]F-DPA<\/em><\/a>, EJNMMI Research, 14, 25.<\/li>\n
  16. Laaksonen S, Saraste M, Nylund M, Hinz R, Snellman A, Rinne J, Matilainen M<\/span> & Airas L<\/strong> (2024): Sex-driven variability in TSPO-expressing microglia in MS patients and healthy individuals<\/em><\/a>, Frontiers in Neurology, 20(15), 1352116.<\/li>\n
  17. Flumian L, Matilainen M<\/span>, Nordhausen K & Taskinen S<\/strong> (2024): Stationary subspace analysis based on second-order statistics<\/em><\/a>, Journal of Computational and Applied Mathematics, 436, 115379.<\/li>\n
  18. Waggan I, Rissanen E, Tuisku J, Matilainen M<\/span>, Parkkola R, Rinne J O & Airas L<\/strong> (2023): Adenosine A2A receptor availability in cerebral gray and white matter of patients with Parkinson’s disease<\/em><\/a>, Parkinsonism & Related Disorders, 113, 105766.<\/li>\n
  19. Polvinen E, Matilainen M<\/span>, Nylund M, Sucksdorff M & Airas L M<\/strong> (2023): TSPO-detectable Chronic Active Lesions Predict Disease Progression in Multiple Sclerosis<\/em><\/a>, Neurology – Neuroimmunology & Neuroinflammation, 10(5), e200133.<\/li>\n
  20. Laaksonen S, Saraste M, Sucksdorff M, Nylund M, Vuorimaa A, Matilainen M<\/span>, Heikkinen J & Airas L<\/strong> (2023): Early prognosticators of later TSPO-PET-measurable microglial activation in multiple sclerosis<\/em><\/a>, Multiple Sclerosis and Related Disorders, 75, 104755.<\/li>\n
  21. Lehto J, Nylund M, Matilainen M<\/span>, Sucksdorff M, Vuorimaa A, Rajander J, Wahlroos S, Hariri P & Airas L<\/strong> (2023): Longitudinal stability of progression-related microglial activity during teriflunomide treatment in patients with multiple sclerosis<\/em><\/a>, European Journal of Neurology, 30, 2365-2375.<\/li>\n
  22. \n
    Saraste<\/span> M<\/span>, Matilainen M<\/span>, Vuorimaa<\/span> A<\/span><\/span><\/strong>, Laaksonen S, Sucksdorff M, Leppert D, Kuhle J & Airas L<\/strong> (2023): <\/span>Association of serum neurofilament light with microglial activation in multiple sclerosis<\/em><\/a>, Journal of Neurology, Neurosurgery & Psychiatry, 94, 698-706.<\/span><\/div>\n<\/li>\n
  23. Lehto J, Sucksdorff M, Nylund M, Raitanen R, Matilainen M<\/span> & Airas\u00a0L<\/strong> (2023): PET-measurable innate immune cell activation reduction in chronic active lesions in PPMS brain after rituximab treatment: a case report<\/em><\/a>, Journal of Neurology, 270, 2329-2332.<\/li>\n
  24. Misin O, Matilainen M<\/span>, Nylund M, Honkonen E, Rissanen E, Sucksdorff M & Airas L <\/strong>(2022): Innate Immune Cell\u2013Related Pathology in the Thalamus Signals a Risk for Disability Progression in Multiple Sclerosis<\/em><\/a>, Neurology – Neuroimmunology & Neuroinflammation, 9(4), e1182.<\/li>\n
  25. Saraste M, Matilainen M<\/span>, Rajda C, Galla Z, Sucksdorff M, V\u00e9csei L & Airas L<\/strong> (2022): Association between microglial activation and serum kynurenine pathway metabolites in multiple sclerosis patients<\/em><\/a>, Multiple Sclerosis and Related Disorders, 59, 103667.<\/li>\n
  26. Vainio S K, Dickens A M, Matilainen M<\/span>, L\u00f3pez-Pic\u00f3n F R, Aarnio R, Eskola O, Solin O, Anthony D C, Rinne J O, Airas L & Haaparanta-Solin M<\/strong> (2022): Dimethyl fumarate decreases short-term but not long-term inflammation in a focal EAE model of neuroinflammation<\/em><\/a>, EJNMMI Research, 12, 6.<\/li>\n
  27. Nylund N, Sucksdorff M, Matilainen M<\/span>, Polvinen E, Tuisku J & Airas L<\/strong> (2021): Phenotyping of multiple sclerosis lesions according to innate immune cell activation using 18 kDa translocator protein-PET<\/em><\/a>, Brain communications, 22, 4(1), fcab301.<\/li>\n
  28. Nordhausen K, Matilainen M<\/span>, Miettinen J, Virta J & Taskinen S<\/strong> (2021): Dimension Reduction for Time Series in a Blind Source Separation Context Using<\/em><\/b> R<\/em><\/a>, Journal of Statistical Software, 98<\/b>(15), 1\u201330.<\/li>\n
  29. Waggan I, Rissanen E, Tuisku J, Matilainen M<\/span>, Helin S, Parkkola R, Rinne J. O. & Airas L <\/strong>(2021): Effect of dopaminergic medication on adenosine 2A receptor availability in patients with Parkinson\u2019s disease<\/em><\/a>, Parkinsonism & Related Disorders, 86, 40-44.<\/li>\n
  30. Saraste M, Bezukladova S, Matilainen M<\/span>, Sucksdorff M, Kuhle J, Leppert D & Airas L <\/strong>(2021): Increased serum glial fibrillary acidic protein associates with microstructural white matter damage in multiple sclerosis<\/em><\/a>. Multiple Sclerosis and Related Disorders, 50, 102810.<\/li>\n
  31. Pan Y, Matilainen M<\/span>, Taskinen S & Nordhausen K<\/strong> (2021): A review of second\u2010order blind identification methods<\/em><\/a>, WIREs Computational Statistics, e1550.<\/li>\n
  32. Hemmil\u00e4 M, Laaksonen I, Matilainen M, Eskelinen A, Haapakoski J, Puhto A-P, Kettunen J, Pamilo K, M\u00e4kel\u00e4 K T<\/strong> (2021): Implant survival of 2,723 vitamin E-infused highly crosslinked polyethylene liners in total hip arthroplasty: data from the Finnish Arthroplasty Register<\/em><\/a>, Acta Orthopaedica, 92(3), 316\u2013322.<\/li>\n
  33. Saraste M, Bezukladova S, Matilainen M<\/span>, Tuisku J, Rissanen E, Sucksdorff M, Laaksonen S, Vuorimaa A, Kuhle J, Leppert D & Airas L<\/strong> (2021): High serum neurofilament associates with diffuse white matter damage in MS<\/em><\/a>, Neurology – Neuroimmunology & Neuroinflammation, 8(1), e926.<\/li>\n
  34. Saraste M, Bezukladova S, Sucksdorff M, Saunavaara V, Rissanen E, Matilainen M & Airas L<\/strong> (2020): Fingolimod treatment reverses signs of diffuse white matter damage in multiple\u00a0\u00a0sclerosis: A pilot study<\/em><\/a>, Multiple Sclerosis and Related Disorders, 48, 102690.<\/li>\n
  35. Smith E, Jaakonm\u00e4ki N, Nylund M, Kupila L, Matilainen M<\/span> & Airas L<\/strong> (2020): Frequency and etiology of acute transverse myelitis in Southern Finland<\/a><\/em>, Multiple Sclerosis and Related Disorders, 46, 102652.<\/li>\n
  36. Sucksdorff M, Matilainen M<\/span>, Tuisku J, Polvinen E, Vuorimaa A, Rokka J, Nylund M, Rissanen E & Airas L<\/strong> (2020): Brain TSPO-PET predicts later disease progression independent of relapses in multiple sclerosis<\/em><\/a>, Brain, 143(11), 3318\u20133330.<\/li>\n
  37. Palom\u00e4ki A, Hemmil\u00e4 M, Laaksonen I, Matilainen M<\/span>, Eskelinen A, Haapakoski J, Puhto A-P, Kettunen J, Manninen M & M\u00e4kel\u00e4 K T<\/strong> (2020): Implant Survival of 6,080 Tritanium Cups in Primary Total Hip Arthroplasty: Data from the Finnish Arthroplasty Register from 2009 to 2017<\/em><\/a>, The Journal of Bone and Joint Surgery, 102(13), 1177-1185.<\/li>\n
  38. Bezukladova S, Tuisku J, Matilainen M<\/span>, Vuorimaa A, Nylund M, Smith S, Sucksdorff M, Mohammadian M, Saunavaara V, Laaksonen S, Rokka J, Rinne J O, Rissanen E & Airas L<\/strong> (2020): Insights into disseminated MS brain pathology with multimodal diffusion tensor and PET imaging<\/em><\/a>, Neurology – Neuroimmunology & Neuroinflammation, 7 (3), e691.<\/li>\n
  39. Airas L, Nylund M, Mannonen I, Matilainen M<\/span>, Sucksdorff M & Rissanen E<\/strong> (2020): Rituximab in the treatment of multiple sclerosis in the Hospital District of Southwest Finland<\/em><\/a>, Multiple Sclerosis and Related Disorders, 40, 101980.<\/li>\n
  40. Miettinen J, Matilainen M<\/span>, Nordhausen K & Taskinen S<\/strong> (2020): Extracting Conditionally Heteroskedastic Components Using Independent Component Analysis<\/em><\/a>, Journal of Time Series Analysis, 41, 293-311.<\/li>\n
  41. H\u00f6gel H, Rissanen E, Barro C, Matilainen M<\/span>, Nylund M, Kuhle J & Airas L<\/strong> (2020): Serum Glial Fibrillary Acidic Protein Correlates with Multiple Sclerosis Disease Progression<\/em><\/a>, Multiple Sclerosis Journal, 6(2), 210-219.<\/li>\n
  42. Sucksdorff M<\/span>, Tuisku J<\/span>, Matilainen M<\/span>, Vuorimaa A<\/span>, Smith S<\/span>, Keitil\u00e4 J<\/span>, Rokka J<\/span>, Parkkola R<\/span>, Nylund M<\/span>, Rinne J<\/span>, Rissanen E &<\/span> Airas L <\/span><\/span><\/strong>(2019): Natalizumab treatment reduces microglial activation in the white matter of the MS brain<\/em><\/a>, Neurology – Neuroimmunology Neuroinflammation, 6(4), e574.<\/li>\n
  43. Matilainen M<\/span>, Croux C, Nordhausen K & Oja H <\/strong>(2019): Sliced Average Variance Estimation for Multivariate Time Series<\/em><\/a>, Statistics, 53(3), 630-655.<\/li>\n
  44. Hemmil\u00e4 M M, Karvonen M, Laaksonen I, Matilainen M<\/span>, Eskelinen A, Haapakoski J, Puhto A-P, Kettunen J, Manninen M & M\u00e4kel\u00e4 K T<\/strong> (2019): Survival of 11,390 Continuum cups in primary total hip arthroplasty based on data from the Finnish Arthroplasty Register<\/a>, <\/em>Acta Orthopaedica, 90 (4),<\/span> 312-317<\/span>.
    \n<\/em><\/li>\n
  45. Matilainen M<\/span>, Nordhausen K & Virta J<\/strong> (2018): On the number of signals in multivariate time series<\/em><\/a>, Proceedings of International Conference on Latent Variable Analysis and Signal Separation (LVA\/ICA), 248-258<\/span>.<\/li>\n
  46. Montonen E, Laaksonen I, Matilainen M<\/span>, Eskelinen A, Haapakoski J, Puhto A P, Leskinen J, Kettunen J, Manninen M, & M\u00e4kel\u00e4 K T<\/strong> (2018): What Is the Long-term Survivorship of Cruciate-retaining TKA in the Finnish Registry?<\/a>,<\/em> Clinical Orthopaedics and Related Research, 476 (6), 1205-1211.<\/li>\n
  47. Matilainen M<\/span>, Croux C, Nordhausen K & Oja H<\/strong> (2017): Supervised dimension reduction for multivariate time series<\/em><\/a>, Econometrics and Statistics, 4, 57-69.<\/li>\n
  48. Matilainen M<\/span>, Miettinen J, Nordhausen K, Oja H & Taskinen S<\/strong> (2017): On Independent Component Analysis with Stochastic Volatility Models<\/a>,<\/em> Austrian Journal of Statistics, 46 (3-4), 57-66.<\/li>\n
  49. Palom\u00e4ki A, Lempainen L, Matilainen M<\/span>, Eskelinen A, Remes V, Virolainen P & M\u00e4kel\u00e4 K T<\/strong> (2017), Survival of uncemented cups from a single manufacturer implanted from 1985 to 2013: Finnish Arthroplasty Register data<\/em><\/a>, Archives of Orthopaedic and Trauma Surgery, pp. 1-10.<\/li>\n
  50. Matilainen M<\/span>, Miettinen J, Nordhausen K, Oja H & Taskinen S<\/strong> (2016): ICA and Stochastic Volatility Models<\/a>. <\/em>In Aivazian S, Filzmoser P and Kharin Y: “Proceedings of the XI International Conference on Computer Data Analysis and Modeling”, 30-37, Publishing Center of BSU, Minsk.<\/li>\n
  51. Toyinbo O, Matilainen M<\/span>, Turunen M, Putus T, Shaughnessy R & Haverinen-Shaughnessy U<\/strong> (2016): Modeling Associations between Principals\u2019 Reported Indoor Environmental Quality and Students\u2019 Self-Reported Respiratory Health Outcomes Using GLMM and ZIP Models<\/em><\/a>, International Journal of Environmental Research and Public Health, 13 (4), 385, 1-12.<\/li>\n
  52. Matilainen M<\/span>, Nordhausen K & Oja H <\/strong>(2015): New Independent Component Analysis Tools for Time Series<\/a>. <\/em>Statistics and Probability Letters, 105, 80-87.<\/li>\n
  53. M\u00e4kel\u00e4 K T, Matilainen M<\/span>, Pulkkinen P, Fenstad A M, Havelin L I, Engesaeter L, Furnes O, Overgaard S, Pedersen A B, K\u00e4rrholm J, <\/strong>Malchau H, Garellick G, Ranstam J & Eskelinen A<\/strong> (2014), Countrywise results of total hip arthroplasty: an analysis of 438,733 hips based on the Nordic Arthroplasty Register Association database<\/em><\/a>, Acta Orthopaedica, 85 (2), 107-116.<\/li>\n
  54. M\u00e4kel\u00e4 K T, Matilainen M<\/span>, Pulkkinen P, Fenstad A M, Havelin L, Engesaeter L, Furnes O, Pedersen A B, Overgaard S, K\u00e4rrholm <\/strong>J, Malchau H, Garellick G, Ranstam J & Eskelinen A<\/strong> (2014): Failure rate of cemented and uncemented total hip replacement: a register study of combined Nordic database of four nations<\/em><\/a>, BMJ, 348.<\/li>\n
  55. Junnila M, Kostensalo I, Virolainen P, Remes V, Matilainen M<\/span>, Vahlberg T, Pulkkinen P, Eskelinen A, It\u00e4l\u00e4 A & M\u00e4kel\u00e4 K<\/strong> (2014): Hip resurfacing arthroplasty versus large head metal on metal total hip arthroplasty: comparison of three designs from the Finnish Arthroplasty Register<\/em><\/a>, Scandinavian Journal of Surgery, 103, 54-59.<\/li>\n
  56. Kostensalo I, Junnila M, Virolainen P, Remes V, Matilainen M<\/span>, Vahlberg T, Pulkkinen P, Eskelinen A & M\u00e4kel\u00e4 K T<\/strong> (2013): Effect of femoral head size on risk of revision for dislocation after total hip arthroplasty: A population-based analysis of 42,379 primary procedures from the Finnish Arthroplasty Register<\/em><\/a>, Acta Orthopaedica, 84 (4), 342-347.<\/li>\n<\/ol>\n

    Software<\/strong><\/h4>\n